Shares of online health platform Hims & Hers Health soared Tuesday after the company announced a partnership with Novo ...

Novo Nordisk launched access to its popular weight loss GLP-1 drug, Wegovy, through multiple telehealth platforms, including ...

Hims & Hers stock has risen by 20% after announcing a partnership to sell the popular weight-loss drug Wegovy.

Novo Nordisk A/S NVO shares lost 2.7% on Friday after a surprising announcement regarding changes to its executive leadership ...

Hims & Hers Health (NYSE:HIMS) reported first-quarter earnings on Monday after the market closed and rocketed 18% after ...

Novo Nordisk's competitive position is strengthening, driven by strong sales growth in Wegovy, Ozempic, and rare diseases.

Investors are buying Hims & Hers Health (NYSE: HIMS) stock hand over fist after the mail-order drugs company reported an ...

Wegovy-maker Novo Nordisk said on Friday its CEO Lars Fruergaard Jorgensen will step down over concerns the company is losing ...

Online health and wellness company Hims & Hers raised $1 billion through convertible senior notes to grow its international ...

The Danish drugmaker, which makes Ozempic and Wegovy, has seen its stock tumble as competition in the weight-loss drug market ...

Novo Nordisk CEO Lars Jørgensen to step down amid increasing pressure from obesity drug competition and recent share price ...

Shares of Hims & Hers Health (NYSE:HIMS) climbed ~36% in the premarket on Tuesday after the telehealth company announced a partnership with Novo Nordisk (NVO) to sell the Danish drugmaker’s popular ...